525 Views

CRT 2023

Best Abstracts: Technology

DES, Imaging Modalities, Biodegradable Scaffolds, Renal Denervation and Emerging Devices & Innovative Therapies

Best Abstracts: Technology | DES, Imaging Modalities, Biodegradeable Scaffolds, Renal Denervation and Emerging Devices & Innovative Therapies

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents In US Patients Undergoing Coronary Revascularization: 1-year Outcomes from the BIOFLOW-VII Trial

Saturday, February 25, 2023

3:12 PM – 3:20 PM ET

Speaker(s)

David E. Kandzari, MD, FACC, FSCAI

Director, Interventional Cardiology, Piedmont Heart Institute; Chief Scientific Officer, Piedmont Healthcare
Piedmont Heart Institute
Atlanta, Georgia, United States

Disclosure(s): Medtronic: Advisor (Ongoing), Clinical Trial Investigator (Ongoing), Clinical Trial Support (Ongoing), Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing)

Disclosure(s):

David E. Kandzari, MD, FACC, FSCAI: Medtronic: Advisor (Ongoing), Clinical Trial Investigator (Ongoing), Clinical Trial Support (Ongoing), Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing)